CoChat

Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells

Open access
Zhou, Guoying, Lieshout, Ruby, van Tienderen, Gilles S., de Ruiter, Valeska, van Royen, Martin E., Boor, Patrick P. C., Magré, Luc, Desai, Jyaysi, Köten, Kübra, Kan, Yik Yang, Ge, Zhouhong, Campos Carrascosa, Lucia, Geuijen, Cecile, Sprengers, Dave, van der Laan, Luc J. W., Verstegen, Monique M. A., Kwekkeboom, Jaap · 2022 · British Journal of Cancer
Cited by 109

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Background: Immunotherapy with immune checkpoint inhibitors (ICIs) is being explored to improve cholangiocarcinoma (CCA) therapy. However, it remains difficult to predict which ICI will be effective for individual patients. Therefore, the aim of this study is to develop a co-culture method with patient-derived CCA organoids and immune cells, which could represent anti-cancer immunity in vitro. Methods: CCA organoids were co-cultured with peripheral blood mononuclear cells or T cells. Flow cytometry, time-lapse confocal imaging for apoptosis, and quantification of cytokeratin 19 fragment (CYFRA) release were applied to analyse organoid and immune cell behaviour. CCA organoids were also cultured in immune cell-conditioned media to analyse the effect of soluble factors. Results: The co-culture system demonstrated an effective anti-tumour organoid immune response by a decrease in live organoid cells and an increase in apoptosis and CYFRA release. Interpatient heterogeneity was observed. The cytotoxic effects could be mediated by direct cell–cell contact and by release of soluble factors, although soluble factors only decreased viability in one organoid line. Conclusions: In this proof-of-concept study, a novel CCA organoid and immune cell co-culture method was established. This can be the first step towards personalised immunotherapy for CCA by predicting which ICIs are most effective for individual patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-022-01839-x

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 109

Metadata

Authors
Zhou, G., Lieshout, R., van Tienderen, G. S., de Ruiter, V., van Royen, M. E., Boor, P. P. C., Magré, L., Desai, J., Köten, K., Kan, Y. Y., Ge, Z., Campos Carrascosa, L., Geuijen, C., Sprengers, D., van der Laan, L. J. W., Verstegen, M. M. A., & Kwekkeboom, J.
Venue
British Journal of Cancer
Published
2022-05-21
Volume
127
Issue
4
Pages
649-660
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W4281253030
Cited by
109
References
13
FWCI
16.74
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells. https://app.cochat.ai/papers/10.1038/s41416-022-01839-x
The paper
Zhou, G., Lieshout, R., van Tienderen, G. S., de Ruiter, V., van Royen, M. E., Boor, P. P. C., Magré, L., Desai, J., Köten, K., Kan, Y. Y., Ge, Z., Campos Carrascosa, L., Geuijen, C., Sprengers, D., van der Laan, L. J. W., Verstegen, M. M. A., & Kwekkeboom, J. (2022). Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells. British Journal of Cancer. https://doi.org/10.1038/s41416-022-01839-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.